Tech Company Financing Transactions
Madison Vaccines Funding Round
Madison Vaccines, operating out of Madison, received $8 million from Venture Investors, State of Wisconsin Investment Board and Venture Management.
Transaction Overview
Company Name
Announced On
1/14/2014
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Venture Investors (Lead Investor) (Paul Weiss)
Proceeds Purpose
The proceeds will support ongoing development of MVI's pipeline, including completion of an expanded Phase 2 clinical trial for MVI-816 in non-metastatic prostate cancer patients with rapidly rising PSA, before the need for surgical or chemical castration (androgen deprivation therapy or ADT).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
505 South Rosa Rd. 201
Madison, WI 53719
USA
Madison, WI 53719
USA
Phone
Website
Email Address
Not Recorded
Overview
The principal mission of Madison, Wisconsin-based MVI is the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. MVI is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Lesniewski
Chief Scientific Officer
Douglas McNeel
Browse more venture capital transactions:
Prev: 1/14/2014: Chrome River Technologies venture capital transaction
Next: 1/14/2014: Invoca venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs